激素治疗使用与年轻发病乳腺癌:绝经前乳腺癌协作组前瞻性队列的汇总分析
该汇总分析纳入10-13个前瞻性队列的459 476名16-54岁女性,随访至55岁,评估外源性激素与年轻发病乳腺癌的关联。任何类型激素治疗与年轻发病乳腺癌无显著关联(HR 0.96),但雌激素治疗呈反向关联(HR 0.86),雌激素加孕激素长期使用(>2年)及子宫卵巢完整女性中呈正关联(HR 1.18和1.15),且与雌激素受体阴性及三阴性亚型关联更强。
要点
- 任何类型激素治疗与年轻发病乳腺癌无显著关联(HR 0.96,95%CI 0.88-1.04)。
- 雌激素治疗与年轻发病乳腺癌呈反向关联(HR 0.86,95%CI 0.75-0.98)。
- 雌激素加孕激素长期使用(>2年)及子宫卵巢完整女性中呈正关联。
核心结论
- 雌激素治疗与年轻发病乳腺癌呈反向关联,雌激素加孕激素治疗在子宫和卵巢完整的女性中与年轻发病乳腺癌发病率升高相关。
- 这些发现与激素使用和晚发乳腺癌的研究结果基本平行,为在年轻女性中建立临床推荐提供了新证据。
研究设计与样本
- 汇总队列分析,纳入来自北美、欧洲、亚洲和澳大利亚的10-13个前瞻性队列。
- 参与队列随访女性至55岁,结局为年轻发病乳腺癌(55岁前诊断)。
- 采用队列分层、多变量校正的Cox比例风险回归估计风险比(HR)和95%CI。
- 基于至55岁的累积风险估计风险差异。
主要发现
- 共纳入459 476名16-54岁女性(平均42.0岁[IQR 35.5-49.2]),其中8455名(2%)发生年轻发病乳腺癌(中位随访7.8年[5.2-11.2])。
- 15%的参与者报告使用激素治疗,最常见的类型为雌激素加孕激素(6%)和单用雌激素(5%)。
- 非使用者的年轻发病乳腺癌累积风险为4.1%。
- 任何类型激素治疗与年轻发病乳腺癌无显著关联(HR 0.96 [95%CI 0.88-1.04]),但曾用雌激素治疗呈反向关联(HR 0.86 [95%CI 0.75-0.98];风险差异 -0.5% [-1.0至-0.0])。
- 曾用雌激素加孕激素治疗与年轻发病乳腺癌的HR为1.10(95%CI 0.98-1.24),长期使用(>2年)呈正关联(HR 1.18 [95%CI 1.01-1.38]),在未行子宫切除或双侧卵巢切除的女性中呈正关联(HR 1.15 [95%CI 1.02-1.31])。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oestrogen plus progestin hormone therapy is an established risk factor for breast cancer in postmenopausal women. We examined the less well-studied association between exogenous hormones and breast cancer in young women, who might use hormone therapy after gynaecological surgery or to relieve perimenopausal symptoms. METHODS: In this pooled cohort analysis, we investigated the relationship between exogenous hormones and breast cancer in young women using data from 10-13 prospective cohorts from North America, Europe, Asia, and Australia. The participating cohorts followed up women for incident breast cancer until age 55 years. We used cohort-stratified, multivariable-adjusted Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% CI for associations of hormone therapy with incident young-onset breast cancer. We also estimated risk differences based on cumulative risk until age 55 years. FINDINGS: We included 459 476 women aged 16-54 years (mean 42·0 years [IQR 35·5-49·2]), of whom 8455 (2%) developed young-onset breast cancer (diagnosed before age 55 years; median follow-up 7·8 years [5·2-11·2]). Overall, 15% of participants reported using hormone therapy, with oestrogen plus progestin hormone therapy (6%) and unopposed oestrogen (5%) being the most common types. Cumulative risk of young-onset breast cancer was 4·1% in non-users. Hormone therapy of any type was not associated with incident young-onset breast cancer (HR 0·96 [95% CI 0·88 to 1·04]), but ever oestrogen hormone therapy use was inversely associated (0·86 [0·75 to 0·98]; risk difference -0·5% [-1·0 to -0·0]). The HR for ever oestrogen plus progestin hormone therapy and young-onset breast cancer was 1·10 (0·98 to 1·24), with positive associations observed for long-term use (1·18 [1·01 to 1·38] for >2 years) and use among women without hysterectomy or bilateral oophorectomy (1·15 [1·02 to 1·31]). Oestrogen hormone therapy and young-onset breast cancer association was similar for all breast cancer subtypes, but oestrogen plus progestin hormone therapy was more strongly associated with oestrogen receptor negative (1·44 [1·11 to 1·88]) and triple-negative disease (1·50 [1·02 to 2·20]) than with other subtypes. INTERPRETATION: Oestrogen hormone therapy use was inversely associated with young-onset breast cancer, and oestrogen plus progestin hormone therapy was associated with higher young-onset breast cancer incidence among women with intact uterus and ovaries. These findings largely parallel results from studies of hormone use and later-onset breast cancer and provide novel evidence for establishing clinical recommendations among younger women. FUNDING: NIH Intramural Research Program.
引用
- O'Brien KM, House MG, Goldberg M, et al. Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group. Lancet Oncol. 2025. PMID: 40609572. doi:10.1016/S1470-2045(25)00211-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。